Gillies Hunter's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Mar 11, 2024
- Accession no.
- 0001415889-24-007533
- Filed
- Mar 11, 2024
- Trade date
- Mar 7, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $219.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gillies HunterCIK 0001868997 | Officer (CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2024 | Common Stock | MOption exerciseAcquired | +8,975 | $2.14 | +$19,206.5 | 12,226 | Direct | |
| Mar 7, 2024 | Common Stock | SSaleDisposed | −8,975 | $24.50 | −$219,887.5 | 3,251 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2024 | Common Stock | MOption exerciseDisposed | −945 | $0.00 | $0 | 15,324 | Direct | |
| Mar 7, 2024 | Common Stock | MOption exerciseDisposed | −8,030 | $0.00 | $0 | 101,510 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.